Anteris Technologies Global Corp. (ASX: AVR) has announced the commencement of its roadshow for the proposed launch of its initial public offering (IPO) in the United States. The company is set to offer 14,800,000 shares of common stock as part of this strategic move.
ATGC has also granted underwriters a 30-day option to purchase an additional 2,220,000 shares, extending the potential scope of the IPO. The company’s common stock is expected to be listed on the Nasdaq Global Market, utilising the ticker symbol “AVR.” This IPO represents a critical step for Anteris as it prepares to expand its financial base and investment reach.
The funds raised from this IPO will primarily be allocated to support the development of the company’s DurAVR® transcatheter heart valve. Additionally, a portion of the proceeds will finance a global study focused on severe aortic stenosis. ATGC plans to use the funds for working capital and other general corporate purposes, reflecting its commitment to advancing its medical innovations. Leading the underwriting for this IPO are TD Cowen, Barclays, and Cantor, with Lake Street Capital Markets acting as the lead manager.
Incorporated on January 29, 2024, ATGC restructured the operations of Anteris Technologies Ltd, an Australian public company specializing in medical devices for structural heart diseases. Notably, it focuses on the DurAVR® transcatheter heart valve, which is distinguished as the first transcatheter aortic valve replacement using bioengineered tissue and the patented ADAPT® anti-calcification tissue technology. Furthermore, the ADAPT® technology has seen extensive clinical use, having been applied to over 55,000 patients worldwide over the past decade. The ComASUR® Delivery System further aids the accurate deployment and positioning of the DurAVR® THV, demonstrating the firm’s technological edge and commitment to patient care.
It’s important to note that the registration statement on Form S-1 has been filed with the Securities and Exchange Commission but has not yet become effective. This procedural step is crucial as ATGC positions itself for its next growth phase through this public offering.
Top Australian Brokers
- City Index - Aussie shares from $5 - Read our review
- Pepperstone - Trading education - Read our review
- IC Markets - Experienced and highly regulated - Read our review
- eToro - Social and copy trading platform - Read our review
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2024.
We’re giving away this valuable research for FREE.
Click below to secure your copy
